CVS Health Aktie 548525 / US1266501006
65.12
USD
0.73
USD
1.13%
07.10.2024
BTT
| Kurse + Charts + Realtime | News + Analysen | Fundamental | Unternehmen | zugeh. Wertpapiere | Aktion | |
|---|---|---|---|---|---|---|
| Kurs + Chart | Chart (gross) | News + Adhoc | Bilanz/GuV | Termine | Strukturierte Produkte | Portfolio |
| Times + Sales | Chartvergleich | Analysen | Schätzungen | Profil | Watchlist | |
| Börsenplätze | Realtime Push | Kursziele | Dividende/GV | |||
| Orderbuch | Analysen | |||||
| Historisch | ||||||
Kurse + Charts + Realtime
News + Analysen
Fundamental
zugeh. Wertpapiere
CVS Health Dividenden Kalender
| Datum | Name | Rendite * | Dividende | Währung |
|---|---|---|---|---|
| 2023 | CVS Health Corp | 3.14 | 2.48 | USD |
| 2022 | CVS Health Corp | 2.42 | 2.26 | USD |
| 2021 | CVS Health Corp | 1.99 | 2.05 | USD |
| 2020 | CVS Health Corp | 2.93 | 2.00 | USD |
| 2019 | CVS Health Corp | 2.69 | 2.00 | USD |
| 2018 | CVS Health Corp | 3.05 | 2.00 | USD |
| 2017 | CVS Health Corp | 2.76 | 2.00 | USD |
| 2016 | CVS Health Corp | 2.25 | 1.78 | USD |
| 2015 | CVS Health Corp | 1.51 | 1.48 | USD |
| 2014 | CVS Health Corp | 1.22 | 1.18 | USD |
Gewinn je Aktie- CVS Health
| 6.4 17 | -0.6 18 | 5.1 19 | 5.5 20 | 6.0 21 | 3.1 22 | 6.5 23 |
Umsatz je Aktie- CVS Health
| 180 17 | 186 18 | 197 19 | 204 20 | 220 21 | 244 22 | 278 23 |
KGV- CVS Health
| 11.3 17 | 14.6 19 | 12.5 20 | 17.3 21 | 29.7 22 | 12.2 23 |
CVS Health Corp: Die Aktie (in USD)
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|---|---|
| Gewinn je Aktie berichtet | 6.44 | -0.57 | 5.08 | 5.46 | 5.95 | 3.14 | 6.47 |
| Gewinn je Aktie unverwässert | 6.47 | -0.57 | 5.10 | 5.48 | 6.00 | 3.16 | 6.49 |
| Gewinn je Aktie verwässert | 6.44 | -0.57 | 5.08 | 5.46 | 5.95 | 3.14 | 6.47 |
| Dividende pro Aktie | 2.00 | 2.00 | 2.00 | 2.00 | 2.05 | 2.26 | 2.48 |
| Gesamtdividendenausschüttung in Mio. | 2’049.00 | 2’038.00 | 2’603.00 | 2’624.00 | 2’625.00 | 2’907.00 | 3’132.00 |
CVS Health Corp: Unternehmenskennzahlen (in USD)
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|---|---|
| Umsatz je Aktie | 180.43 | 186.38 | 196.61 | 204.46 | 219.67 | 243.98 | 277.73 |
| KGV (Jahresendkurs, EPS unverwässert) | 11.26 | - | 14.62 | 12.50 | 17.33 | 29.72 | 12.21 |
| KGV (Jahresendkurs, EPS verwässert) | 11.26 | - | 14.62 | 12.50 | 17.33 | 29.72 | 12.21 |
| KGV (Jahresendkurs) | 11.26 | - | 14.62 | 12.50 | 17.33 | 29.72 | 12.21 |
| Dividendenrendite Jahresende in % | 2.76 | 3.05 | 2.69 | 2.93 | 1.99 | 2.42 | 3.14 |
| Eigenkapitalquote in % | 39.62 | 29.54 | 28.61 | 29.23 | 31.34 | 30.18 | 29.73 |
| Fremdkapitalquote in % | 60.38 | 70.46 | 71.39 | 70.77 | 68.66 | 69.82 | 70.27 |
CVS Health Corp: GuV (in Mio. USD)
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|---|---|
| Umsatzerlöse | 184’765.00 | 194’578.00 | 256’577.00 | 268’654.00 | 291’935.00 | 322’787.00 | 358’273.00 |
| Umsatzveränderung in % | 4.08 | 5.31 | 31.86 | 4.71 | 8.67 | 10.57 | 10.99 |
| Bruttoergebnis vom Umsatz | 28’547.00 | 31’537.00 | 45’329.00 | 48’994.00 | 51’872.00 | 54’614.00 | 54’928.00 |
| Bruttoergebnisveränderung in % | -1.23 | 10.47 | 43.73 | 8.09 | 5.87 | 5.29 | 0.57 |
| Operatives Ergebnis | 9’987.00 | 10’790.00 | 12’704.00 | 13’922.00 | 14’938.00 | 16’402.00 | 15’583.00 |
| Veränderung Operatives Ergebnis in % | -6.06 | 8.04 | 17.74 | 9.59 | 7.30 | 9.80 | -4.99 |
| Ergebnis vor Steuern | 8’268.00 | 1’406.00 | 8’997.00 | 9’770.00 | 10’420.00 | 5’628.00 | 11’173.00 |
| Veränderung Ergebnis vor Steuern in % | -4.27 | -82.99 | 539.90 | 8.59 | 6.65 | -45.99 | 98.53 |
| Ergebnis nach Steuer | 6’598.00 | -597.00 | 6’629.00 | 7’179.00 | 7’910.00 | 4’149.00 | 8’344.00 |
| Veränderung Ergebnis nach Steuer in % | 24.73 | - | - | 8.30 | 10.18 | -47.55 | 101.11 |
CVS Health Corp: Bilanz (in Mio. USD)
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|---|---|
| Gesamtverbindlichkeiten | 57’436 | 139’667 | 160’124 | 168’788 | 165’115 | 164’950 | 181’094 |
| Langzeit Gesamtverbindlichk. pro Aktie | 26.42 | 73.87 | 82.04 | 81.50 | 73.61 | 73.24 | 79.12 |
| Eigenkapital | 37’695 | 58’543 | 64’170 | 69’701 | 75’381 | 71’315 | 76’636 |
| Veränderung Eigenkapital in % | 2.34 | 54.48 | 9.68 | 8.65 | 8.19 | -5.41 | 7.67 |
| Bilanzsumme | 95’131 | 198’210 | 224’294 | 238’489 | 240’496 | 236’265 | 257’730 |
| Veränderung Bilanzsumme in % | 0.71 | 108.35 | 13.16 | 6.33 | 0.84 | -1.76 | 9.09 |
CVS Health Corp: Sonstige Angaben (in USD)
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|---|---|
| Gewinn je Aktie (unverwässert) | 6.47 | -0.57 | 5.10 | 5.48 | 6.00 | 3.16 | 6.49 |
| Veränderung Gewinn je Aktie (unverwässert) in % | 31.24 | -108.81 | - | 7.63 | 9.35 | -47.27 | 105.33 |
| Gewinn je Aktie (verwässert) | 6.44 | -0.57 | 5.08 | 5.46 | 5.95 | 3.14 | 6.47 |
| Veränderung Gewinn je Aktie (verwässert) in % | 31.43 | -108.85 | - | 7.56 | 8.94 | -47.31 | 106.26 |
| Anzahl Mitarbeiter | 246’000 | 295’000 | 290’000 | 300’000 | 300’000 | 300’000 | 300’000 |
| Veränderung Anzahl Mitarbeiter in % | -1.60 | 19.92 | -1.69 | 3.45 | 0.00 | 0.00 | 0.00 |
CVS Health Corp Termine
| Unternehmen | Event | Datum |
|---|---|---|
| CVS Health Corp | Quartalszahlen | 06.11.24 |
| CVS Health Corp | Quartalszahlen | 05.02.25 |
| CVS Health Corp | Quartalszahlen | 30.04.25 |
| CVS Health Corp | Quartalszahlen | 06.08.25 |
| CVS Health Corp | Quartalszahlen | 05.11.25 |
CVS Health Corp vergangene Termine
| Terminart | Info | Datum |
|---|---|---|
| Quartalszahlen | Q2 2024 Earnings Release | 07.08.24 |
Aktionärsstruktur
| Inhaber | in % |
|---|---|
| Freefloat | 99.79 |
| The Vanguard Group, Inc. | 9.35 |
| Vanguard Group, Inc. (Subfiler) | 8.79 |
| Dodge & Cox | 4.90 |
| Capital Research & Management Co. (World Investors) | 4.45 |
| State Street Corp. | 4.34 |
| Dodge & Cox Stock Fund | 3.28 |
| Vanguard Total Stock Market ETF | 3.16 |
| Capital Research & Management Co. (Global Investors) | 2.82 |
| Vanguard 500 Index Fund | 2.61 |
| BlackRock Fund Advisors | 2.43 |
| BlackRock Institutional Trust Co. NA | 2.25 |
| Geode Capital Management LLC | 2.06 |
| Washington Mutual Investors Fund | 1.95 |
| American Funds Income Fund of America | 1.85 |
*Die Summe der Anteile kann 100% überschreiten, da bestimmte Anteilseigner zum Freefloat dazu gerechnet wurden.
Personal
| 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|
| Personal am Ende des Jahres | 290’000 | 300’000 | 300’000 | 300’000 | 300’000 |
| Umsatz pro Mitarbeiter in Mio. EUR | 0.88 | 0.90 | 0.97 | 1.08 | 1.19 |
Bilanz (in Mio. USD) - Aktiva
| 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|
| Summe Umlaufvermögen | 50’302 | 56’369 | 60’008 | 65’682 | 67’858 |
| Summe Anlagevermögen | 152’866 | 154’431 | 151’074 | 141’747 | 155’846 |
| Summe Aktiva | 224’294 | 238’489 | 240’496 | 236’265 | 257’730 |
Bilanz (in Mio. USD) - Passiva
| 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|
| Gesamtverschuldung/ -verbindlichkeiten | 89’002 | 85’042 | 75’999 | 70’732 | 79’385 |
| Summe Fremdkapital | 160’124 | 168’788 | 165’115 | 164’950 | 181’094 |
| Summe Eigenkapital | 64’170 | 69’701 | 75’381 | 71’315 | 76’636 |
| Summe Passiva | 224’294 | 238’489 | 240’496 | 236’265 | 257’730 |
Adresse
| 1 CVS Drive, 02895 Woonsocket | |
| Telefon | +1 (401) 765-1500 |
| URL | http://www.cvshealth.com |
Management
|
Alec Cunningham
Executive Vice President |
|
Alecia A. DeCoudreaux
Independent Director |
|
Amy Bricker
Chief Product Officer-Consumer & Executive VP |
|
Anne M. Finucane
Independent Director |
|
Bryan Cook
Regional Director-Real Estate |
|
C. David Brown
Independent Director |
|
Carol Ann DeNale
Treasurer & Senior Vice President |
|
Chandra McMahon
Chief Information Security Officer & Senior VP |
|
Charles Golden
SVP-Construction & Property Administration |
|
Danni Gallagher
Vice President-Construction |
|
David A. Falkowski
Chief Compliance Officer & Executive VP |
|
David Berman
Director-Real Estate Metro NY |
|
Deborah LeClerc
Coordinator-Real Estate |
|
Fernando G. Aguirre
Independent Director |
|
Heidi B. Capozzi
Chief People Officer & Executive Vice President |
|
Holly Jensen
Director-Real Estate & Executive Advisor |
|
J. David Joyner
Executive Vice President |
|
J. Scott Kirby
Independent Director |
|
James D. Clark
Chief Accounting Officer, Senior VP & Controller |
|
Jason L. Monroe
Sales Manager |
|
Jean-Pierre Millon
Independent Director |
|
Jeffrey R. Balser
Independent Director |
|
Jenice Tom
Director-Real Estate Market Research & Analytics |
|
Karen S. Lynch
President, Chief Executive Officer & Director |
|
Katerina Guerraz
Chief Operating Officer-Health Care Benefits |
|
Kristina V. Fink
Secretary, Chief Governance Officer & Senior VP |
|
Larry Webb
Director-Real Estate |
|
Laurence McGrath
SVP-Business Development & Investor Relations |
|
Madi Rajulapalli
Regional Medical Director-Medicare Case Management |
|
Mary Lovelace Schapiro
Independent Director |
|
Matthew Tamke
Director-OTC Health Solutions |
|
Melissa A. Schulman
Senior Vice President-Government & Public Affairs |
|
Michael F. Mahoney
Independent Director |
|
Michael Kurimcak
Vice President-Real Estate |
|
Michael T. Pykosz
President-Health Services |
|
Michelle A. Peluso
Executive Vice President & Chief Customer Officer |
|
Nancy-Ann M. DeParle
Independent Director |
|
Per G. H. Lofberg
Executive Vice President |
|
Preet H. Michelson
Vice President-Human Resources |
|
Prem S. Shah
Chief Pharmacy Officer & President-Pharmacy |
|
Robert Holtzman
Regional Real Estate Manager |
|
Robin Peterson
Real Estate Director |
|
Roger N. Farah
Chairman |
|
Samrat S. Khichi
Chief Policy Officer, General Counsel & EVP |
|
Shari M. Slate
SVP, Chief Diversity, Equity & Inclusion Officer |
|
Sheryl A. Burke
Chief Sustainability Officer & Senior VP |
|
Sreekanth Chaguturu
Chief Medical Officer & Executive Vice President |
|
Stephen Frumento
VP-Real Estate & Corporate Acquisitions |
|
Stephen LaBonge
Regional Director-Real Estate |
|
Thomas F. Cowhey
Chief Financial Officer & Senior Vice President |
|
Thomas S. Moffatt
Vice President & Senior Legal Counsel |
|
Tilak Mandadi
EVP, Chief Data, Digital & Technology Officer |
|
Todd Galusha
Real Estate Advisor |
|
Tracey Drake Weber
Senior VP-Digital Products, UX & Operations |